Everand Logo

Welcome to Everand!

  • Discover millions of ebooks, audiobooks, and so much more with a free trial

    Only $11.99/month after trial. Cancel anytime.

    Clinical Updates in Rheumatoid Arthritis: New Strategies to Target Remission and Individualize Comprehensive Care
    Clinical Updates in Rheumatoid Arthritis: New Strategies to Target Remission and Individualize Comprehensive Care
    Clinical Updates in Rheumatoid Arthritis: New Strategies to Target Remission and Individualize Comprehensive Care
    Ebook106 pages41 minutes

    Clinical Updates in Rheumatoid Arthritis: New Strategies to Target Remission and Individualize Comprehensive Care

    By Jonathan Kay, MD and Alan J. Kivitz, MD, CPI

    ()

    Read preview

    About this ebook

    This eHealth Source™ activity has been developed as a text-based eBook with additional video clips to update clinicians on the latest evidence-based information to guide RA management, with a focus on inhibition of IL-6 signaling.

    LanguageEnglish
    PublisherIntegritas Communications
    Release dateFeb 23, 2018
    ISBN9780998419428
    Clinical Updates in Rheumatoid Arthritis: New Strategies to Target Remission and Individualize Comprehensive Care

    Related to Clinical Updates in Rheumatoid Arthritis

    Related ebooks

    Medical For You

    View More
    View More

    Related podcast episodes

    Related articles

    • Article

      Opinion: Why Medical School Should Start At Age 28

      Feb 17, 2020

      The axe of autonomy must rip at the root of doctors' dependence on the fickle medical profession for career and life satisfaction and financial security. Medicine should be an individual's…

      6 min read

    • Article

      A DNA Test Saved My Life

      Aug 23, 2022

      A DNA Test Saved My Life
      4 min read

    • Article

      The Integrating Fields Of Medicine + Oncology

      Aug 31, 2018

      People diagnosed with cancer and their families often use therapies such as acupuncture, exercise, diet and meditation to cope with the physical, emotional, and spiritual effects of the cancer, and in search of relief from symptoms that their convent

      5 min read

    • Article

      A New Cancer Care Dilemma: Patients Want Immunotherapy Even When Evidence Is Lacking

      Jun 4, 2018

      Doctors' new dilemma: Can they justify prescribing an immune therapy when it hasn’t been tested for a patient’s particular type of cancer?

      5 min read

    • Article

      Opioid Use Creeps Back After Weight-Loss Surgery

      Jun 6, 2017

      Research finds that the proportion of adults with severe obesity who use prescription opioid medications declines in the months after bariatric surgery, but then increases within a few years after the surgery, eventually surpassing the pre-surgery pe

      3 min read

    • Article

      Upfront

      Mar 22, 2020

      Upfront
      19 min read

    • Article

      Expanding Precision Medicine

      Jul 30, 2020

      Expanding Precision Medicine
      9 min read

    • Article

      Inthe Blood

      Nov 24, 2019

      Inthe Blood
      10 min read

    • Article

      Opinion: Unnecessary Exclusions Shut Patients Out Of Clinical Trials

      Apr 5, 2018

      Many sick patients are being denied the opportunity to test new drugs that might save their lives. It’s time for this to change.

      2 min read

    • Article

      All Together Now

      Apr 29, 2022

      All Together Now
      4 min read

    • Article

      Opinion: Drug Sensitivity And Resistance Testing Could Make ‘Right To Try’ A Real Thing

      Oct 9, 2018

      There's no catalog of available drugs that can help patients pursuing #RightToTry options. An updated technique once developed for cancer might match patients with experimental drugs.

      3 min read

    • Article

      A Quick Round of Steroids May Bring Big Risks

      Apr 18, 2017

      Every year, millions of Americans get short-term prescriptions for steroids, such as prednisone, often for back pain, allergies, or other relatively minor ailments. Though these prescriptions are quite common, doctors should consider the potential he

      4 min read

    • Article

      Drug In The Pipeline Helps Stem Cell Transplants Too

      Apr 29, 2018

      An investigational drug in clinical trials for rheumatoid arthritis also prevents a common, life-threatening side effect of stem cell transplants, new research shows. Studying mice, the researchers found the drug prevented what’s known as graft-versu

      3 min read

    Related categories

    Reviews for Clinical Updates in Rheumatoid Arthritis

    0 ratings

    0 ratings0 reviews

    What did you think?

    Tap to rate

    Review must be at least 10 words

      Book preview

      Clinical Updates in Rheumatoid Arthritis - Jonathan Kay, MD

      CLINICAL UPDATES IN RHEUMATOID ARTHRITIS

      New Strategies to Target Remission and Individualize Comprehensive Care

      Jonathan Kay, MD and Alan J. Kivitz, MD, CPI

      PRONOUN

      © 2017-2018 Integritas Communications.

      All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.

      TABLE OF CONTENTS

      Faculty: Jonathan Kay, MD

      Alan J. Kivitz, MD, CPI

      Preamble: Target Audience

      Statement of Need/Program Overview

      References

      Educational Objectives

      Physician Accreditation Statement

      Physician Credit Designation

      Global Contact Information

      Instructions to Receive Credit

      Fee Information & Refund/Cancellation Policy

      Disclosure of Conflicts of Interest

      Disclosure of Unlabeled Use

      Disclaimer

      Chapter 1: Rheumatoid Arthritis Pathophysiology and the Roles of IL-6

      Articular and Extra-Articular Disease Manifestations

      Factors Contributing to RA Development: A Focus on IL-6

      Key Clinical Highlights

      References

      Chapter 2: Comprehensively Evaluating Patients With Rheumatoid Arthritis

      Core Tenets of Treating to Target in RA

      Validated Measures of Disease Activity

      Additional Evaluation Considerations

      Key Clinical Highlights

      References

      Chapter 3: Biologic Inhibitors of IL-6 Signaling

      Tocilizumab

      Sarilumab

      Key Clinical Highlights

      References

      Chapter 4: Individualizing Rheumatoid Arthritis Management and the Role of IL-6 Inhibition

      Shared Clinical Decision-Making in Rheumatoid Arthritis Management

      Positioning Inhibitors of IL-6 Signaling in RA Treatment Algorithms

      Key Clinical Highlights

      References

      Rheumatoid Arthritis Clinical Resource Center™: Guidelines

      Patient Resources

      American College of Rheumatology Disease Overview

      American College of Rheumatology Patient Education Videos

      Arthritis Foundation

      Handout on Health: Rheumatoid Arthritis

      Rheumatoid Arthritis Support Network

      Suggested Reading

      Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

      Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

      IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.

      Measures of rheumatoid arthritis disease activity.

      The pathogenesis of rheumatoid arthritis.

      Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

      Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

      Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study.

      Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors.

      Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

      Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.

      Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.

      Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

      CME Posttest

      FACULTY

      JONATHAN KAY, MD

      Timothy S. & Elaine L. Peterson Chair in Rheumatology & Professor of Medicine

      University of Massachusetts Medical School

      Director of Clinical Research, Rheumatology

      UMass Memorial Medical Center

      Worcester, Massachusetts

      Dr. Jonathan Kay is Professor of Medicine at the University of Massachusetts Medical School and a physician at UMass Memorial Medical Center in Worcester, where he directs clinical research in the Division of Rheumatology. He received his medical degree from the University of California School of Medicine in San Francisco, California. He then completed an internship and residency at the Hospital of the University of Pennsylvania in Philadelphia and fellowships in rheumatology and

      Enjoying the preview?
      Page 1 of 1